Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
1(33.3%)
Phase 3
1(33.3%)
Phase 2
1(33.3%)
3Total
N/A(1)
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07468526Phase 3Not Yet Recruiting

An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria

Role: collaborator

NCT04157595Not ApplicableCompleted

Mackenzie's Mission: The Australian Reproductive Carrier Screening Project

Role: collaborator

NCT01214395Phase 2Completed

Nasal Tea Tree Oil for the Prevention of Infections in PD Patients

Role: lead

All 3 trials loaded